|
Apr 8
|
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
|
|
Apr 5
|
Theratechnologies Appoints Elina Tea to its Board of Directors
|
|
Apr 3
|
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
|
|
Mar 28
|
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
|
|
Mar 22
|
Theratechnologies Announces Update on its Preclinical Oncology Research Program
|
|
Mar 22
|
Theratechnologies Appoints Jordan Zwick to its Board of Directors
|
|
Mar 21
|
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
|
|
Jan 2
|
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
|
|
Oct 26
|
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
|
|
Oct 25
|
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
|
|
Oct 24
|
Theratechnologies Announces Operational Update
|
|
Aug 5
|
10 Oversold Canadian Stocks To Buy
|
|
Aug 5
|
10 Oversold Global Stocks To Buy
|
|
May 25
|
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
|